Vincent O'Neill - 14 Mar 2023 Form 4/A Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Executive Vice President, Chief of Product Development and Medical Officer
Signature
/s/ Richard Steinhart, as Attorney-in-Fact for Vincent O'Neill
Issuer symbol
BTAI
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4/A
Filing time
18 Jun 2024, 21:22:49 UTC
Date Of Original Report
16 Mar 2023
Previous filing
24 Jan 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BTAI Common Stock 3,158 14 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BTAI Restricted Stock Units 0 14 Mar 2023 Common Stock 0 Direct F1
holding BTAI Stock Option (Right to Buy) 0 14 Mar 2023 Common Stock 0 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the amount previously reported in the Form 4 filed on March 16, 2023 (the "Original Form 4") that inadvertently reported an award of (i) 9,000 restricted stock units ("RSUs") and (ii) options to purchase 32,000 shares of the Issuer's common stock (the "Options"). The Reporting Person was not granted such RSUs and Options and does not beneficially own any shares underlying the awards reported on the Original Form 4.

Remarks:

Executive Vice President, Chief of Product Development and Medical Officer